PCI Biotech ASA Equity Issue
Share the transaction
January 2017 – PCI Biotech ASA Equity Issue
About the deal
In 2017 Bryan, Garnier & Co acted as sole manager in a fully underwritten rights issue for PCI Biotech, raising gross proceeds of NOK 70m.
Deal team
Erik Furnes | Managing Director | Oslo | Investment Banking | efurnes@bryangarnier.com
Rolf Henning Lem | Director | Oslo | Investment Banking | rlem@bryangarnier.com
Håkon Benjaminsen | Director | Oslo | Investment Banking | hbenjaminsen@bryangarnier.com
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities. PCI Biotech is listed at Oslo Børs.